Introduction to the indications and clinical application of Almonertinib

Almonertinib (Almonertinib) is a new oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR pan>TKI), specifically developed for patients with EGFR gene mutation-positive non-small cell lung cancer (NSCLC). Compared with the first and second generation EGFR-TKI, the significant advantage of ametinib is that it can selectively inhibit EGFR sensitive mutations (such as Exon19 deletions and pan>L858R point mutation) and drug-resistant mutation T790M, while the inhibitory effect on wild-type EGFR is relatively weak, thereby improving anti-tumor efficacy while reducing toxicity to normal cells. This precise targeting effect makes ametinib an important first- and second-line treatment option for patients with advanced and metastatic EGFR mutated NSCLC.

In clinical application, the primary indication of ametinib is advanced or metastatic EGFR mutation-positive non-small cell lung cancer. For newly treated patients, first-line use of ametinib can effectively delay disease progression, improve patients' quality of life, and reduce adverse reactions during treatment. For second-line treatment, especially those patients who have developed T790M resistance mutations after previously receiving first- or second-generation EGFR-TKI treatment, Ametinib can accurately inhibit drug-resistant mutations, control tumor progression, and play a positive role in brain metastases in some patients. Its ability to penetrate the blood-brain barrier allows it to also show significant efficacy in patients with central nervous system (CNS) involvement, which is difficult for many early EGFR-TKI drugs to achieve.

Clinical trial data show that ametinib has good efficacy and tolerability in patients with EGFR mutationsNSCLC. In first-line treatment trials, the objective response rate (ORR) has been significantly improved, and most patients can achieve long-term disease control; in second-line T790M-resistant patients, the ORR of ametinib is comparable to that of osimertinib (Osimertinib) is equivalent and can effectively inhibit the development of brain metastases. In terms of side effects, ametinib is generally tolerable. The most common adverse reactions include mild to moderate rash, diarrhea, thrombocytopenia, and mild liver function abnormalities. The incidence of serious adverse reactions is low, and most patients can be relieved through symptomatic treatment or dose adjustment. Compared with early-stage EGFR-TKI, ametinib has certain advantages in safety, making long-term treatment more feasible.

The clinical application of ametinib continues to expand. In addition to patients with advanced NSCLC, researchers are exploring its potential role in adjuvant therapy and in patients with early stage EGFR mutated NSCLC. For example, in postoperative adjuvant therapy, ametinib is expected to improve disease-free survival (DFS) by inhibiting minimal residual disease. In addition, with the development of precision medicine, EGFR gene mutation detection has become an important step before medication. By detecting Exon19 deletion, L858R point mutation and T790M resistance mutation, doctors can determine whether the patient is suitable for ametinib, thereby achieving personalized treatment. In clinical practice, doctors also need to conduct individualized dose adjustments and follow-up based on the patient's age, liver and kidney function, comorbid diseases, and previous medication history to maximize efficacy and ensure medication safety.

In general, ametinib has shown significant advantages in the treatment of EGFRmutatedNSCLC due to its high selectivity, good tolerability and precise inhibition of drug-resistant mutations. It not only provides an effective first-line treatment option for newly treated patients, but also provides a feasible option for second-line treatment for drug-resistant patients. Especially in patients with central nervous system involvement, ametinib can provide considerable improvement in efficacy, help control the progression of brain metastases, and improve patients' quality of life. With the accumulation of more clinical data and enriched application experience, ametinib will play a more important role in the treatment of NSCLC and bring new long-term disease management solutions and hope to patients with EGFR mutations.

Reference link:https://www.drugs.com